yingweiwo

Creatinine (NSC13123)

Alias: NSC 13123; NSC-13123; NSC13123
Cat No.:V5086 Purity: ≥98%
Creatinine (also known as NSC13123) is a degradation/break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body.
Creatinine (NSC13123)
Creatinine (NSC13123) Chemical Structure CAS No.: 60-27-5
Product category: Endogenous Metabolite
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10g
25g
50g
100g
200g
Other Sizes

Other Forms of Creatinine (NSC13123):

  • N-Methylhydantoin
  • 5-Hydroxytryptamine creatinine sulfate monohydrate
  • Creatinine-D3
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Creatinine (also known as NSC13123) is a degradation/break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body. Creatinine is also used as a bulking agent for freeze drying.

Biological Activity I Assay Protocols (From Reference)
References

[1]. Allen, P.J., Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value. Neurosci Biobehav Rev, 2012. 36(5): p. 1442-62.

[2]. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med, 2006. 145(4): p. 247-54.

Additional Infomation
Creatinine is a lactam obtained by formal cyclocondensation of creatine. It is a metabolite of creatine. It has a role as a diagnostic agent and a human metabolite. It is a lactam and an imidazolidinone. It is functionally related to a creatine.
Creatinine has been used in trials studying the treatment of Amyotrophic Lateral Sclerosis.
Krebiozen has been reported in Punica granatum, Morus alba, and other organisms with data available.
Creatinine is the breakdown product of creatine, a constituent of muscle tissue, that is excreted by the kidney and whose serum level is used to evaluate kidney function.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C4H7N3O
Molecular Weight
113.1179
Exact Mass
113.058
CAS #
60-27-5
Related CAS #
60-27-5 (Creatinine); 616-04-6 (N-Methylhydantoin, a product of degradation of creatinine by bacteria); 61-47-2 (5-Hydroxytryptamine creatinine sulfate monohydrate); 143827-20-7 (Creatinine-D3)
PubChem CID
588
Appearance
White to off-white solid powder
Density
1.5±0.1 g/cm3
Boiling Point
184.3±23.0 °C at 760 mmHg
Melting Point
295 °C (dec.)(lit.)
Flash Point
65.3±22.6 °C
Vapour Pressure
0.2±0.8 mmHg at 25°C
Index of Refraction
1.651
LogP
-1.68
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
1
Rotatable Bond Count
0
Heavy Atom Count
8
Complexity
151
Defined Atom Stereocenter Count
0
InChi Key
DDRJAANPRJIHGJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C4H7N3O/c1-7-2-3(8)6-4(7)5/h2H2,1H3,(H2,5,6,8)
Chemical Name
2-Imino-1-methylimidazolidin-4-one
Synonyms
NSC 13123; NSC-13123; NSC13123
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 8.8402 mL 44.2008 mL 88.4017 mL
5 mM 1.7680 mL 8.8402 mL 17.6803 mL
10 mM 0.8840 mL 4.4201 mL 8.8402 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Efficacy of the medical compound of teneligliptin 20 mg and canagliflozin 100 mg with Free Style Libre
CTID: UMIN000029015
Phase:    Status: Recruiting
Date: 2017-09-05
The study about changes of the Summary of Diabetes Self-Care Activities (SDSCA) measure in patients who use Free Style Libre.
CTID: UMIN000029016
PhaseNot applicable    Status: Recruiting
Date: 2017-09-05
The study on renal excretion drug dosage adjustment by point of care test in community pharmacy
CTID: UMIN000024171
Phase:    Status: Complete: follow-up complete
Date: 2016-10-01
Study about effects of macronutrient distribution to glucose control and treatment satisfaction in type 2 diabetes
CTID: UMIN000022132
PhaseNot applicable    Status: Recruiting
Date: 2016-04-29
Study about the effect of minutes and the number of times of dietary intervention to QOL and dietary compliance.
CTID: UMIN000021952
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2016-04-18
View More

Differences about effectiveness of CGM and treatment satisfaction between dulaglutide and omarigliptin.
CTID: UMIN000021953
PhaseNot applicable    Status: Recruiting
Date: 2016-04-18


Influences of anticoagulant treatment (RIbaroxaban vs warfarin) on Systemic inflammative markers in patients with Heart Failure and atrial fibrillation
CTID: UMIN000021649
Phase:    Status: Recruiting
Date: 2016-04-01
AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study
CTID: UMIN000016612
Phase:    Status: Complete: follow-up complete
Date: 2015-02-23
An open label, single institute, single arm trial of efficacy and safety of the anti-RANKL monoclonal antibody (Denosumab) for patients with steroid-induced osteoporosis
CTID: UMIN000011461
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2013-08-12
Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan.
CTID: UMIN000008390
Phase:    Status: Complete: follow-up complete
Date: 2012-07-09
Mechanisms of antiproteinuric effects of azelnidipine in hypertensive patients with type 2 diabetes mellitus
CTID: UMIN000007456
Phase:    Status: Complete: follow-up continuing
Date: 2012-03-08
Combination effects of an angiotensin receptor blocker and an L/T type calcium channel blocker in hypertensive patients with type 2 diabetes mellitus
CTID: UMIN000007463
Phase:    Status: Complete: follow-up continuing
Date: 2012-03-07
Renoprotective Effect of Valsartan versus Spherical Carbon Adsorbent in Children in the Conservative Phase of Chronic Kidney Disease: A Randomized Controlled Trial
CTID: UMIN000006917
Phase:    Status: Complete: follow-up complete
Date: 2011-12-20
A multicenter, open-label trial to evaluate the effects of zoledronic acid on circulating tumor cells in patients with castration resistant prostate cancer (CRPC) with bone metastasis.
CTID: UMIN000006736
Phase: Phase II    Status: Complete: follow-up complete
Date: 2011-11-16
Effect of a standard dose of telmisartan combined with amlodipine and trichlormethiazide versus a high dose of telmisartan combined with trichlormethiazide on urinary excretion of albumin in hypertensive patients with type 2 diabetes mellitus
CTID: UMIN000005170
Phase:    Status: Complete: follow-up complete
Date: 2011-03-02
An Open label multi- facilities cooperation randomized control trial to verify renoprotective effects of Aliskiren treatment in the chronic kidney disease (CKD).
CTID: UMIN000003678
Phase:    Status: Complete: follow-up complete
Date: 2010-07-01
A randomized controlled trial of intra-arterial infusion of CDDP for hepatocellular carcinoma to prevent intra-hepatic metastasis after curative resection
CTID: UMIN000001138
Phase: Phase I,II    Status: Complete: follow-up complete
Date: 2008-05-01
An open label multi facilities cooperation randomized control trial to verify renoprotective effects of pioglitazone therapy in diabetic nephropathy
CTID: UMIN000001126
Phase:    Status: Complete: follow-up complete
Date: 2008-04-30

Contact Us